繁体中文
设为首页
加入收藏
当前位置:药品说明书与价格首页 >> 抗感染类 >> 药品目录 >> 抗生素类 >> 青霉素类 >> PIPERACILLIN/TAZOBACTAM(哌拉西林/他唑巴坦)注射剂

PIPERACILLIN/TAZOBACTAM(哌拉西林/他唑巴坦)注射剂

2012-10-27 23:23:05  作者:新特药房  来源:中国新特药网天津分站  浏览次数:175  文字大小:【】【】【
简介: 英文商品名:PIPERACILLIN/TAZOBACTAM(generic equivalent to Zosyn)商品译名: 哌拉西林/他唑巴坦(相当于ZOSYN仿制药)药品译名: 哌拉西林钠/他唑巴坦钠规格PIPERACILLIN/TAZOBACTAM(generic equivalent ...

英文商品名:PIPERACILLIN/TAZOBACTAM(generic equivalent to Zosyn)
商品译名: 哌拉西林/他唑巴坦(相当于ZOSYN仿制药)
药品译名: 哌拉西林钠/他唑巴坦钠
规格PIPERACILLIN/TAZOBACTAM(generic equivalent to Zosyn) (3/0.375)g/vial 10vials/box、PIPERACI​LLIN(generic equivalent to Pipracil) 3G/VIAL 10VIALS/BOX
【药理毒理】本品为哌拉西林钠和他唑巴坦钠组成的复方制剂。哌拉西林为广谱半合成青霉素类抗生素,他唑巴坦为β-内酰胺酶抑制剂。
本品对哌拉西林敏感的细菌和产β-内酰胺酶耐哌拉西林的下列细菌有抗菌作用: 革兰氏阴性菌:大多数质粒介导的产和不产β-内酰胺酶的下列细菌:大肠杆菌、克雷伯氏菌属(催产克雷伯氏菌、肺炎克雷伯氏菌)、变形杆菌属(奇异变形杆菌、普通变形杆菌)、沙门氏菌属、志贺氏菌属、淋病奈瑟氏菌、脑膜炎双球菌、莫根杆菌属、嗜血杆菌属(流感和副流感嗜血杆菌)、多杀巴氏杆菌、耶尔森菌属、弯曲菌属、阴道加特纳菌。染色体介导的产和不产β-内酰胺酶的下列细菌:弗劳地枸椽酸菌、产异枸椽酸菌、普鲁威登斯菌属、莫根杆菌、沙雷菌属(粘质沙雷氏菌、液压沙雷氏菌)、绿脓杆菌和其他假单胞菌属(洋葱假单胞菌、荧光假单胞菌)、嗜麦芽假单胞菌、不动杆菌属。革兰氏阳性菌:产和不产β-内酰胺酶的下列细菌:链球菌属(肺炎链球菌、酿脓链球菌、牛链球菌、无乳链球菌、绿色链球菌、C族和G族链球菌)、肠球菌属(粪肠球菌、屎肠球菌)、金黄色葡萄球菌(不包括MRSA)、腐生葡萄球菌、表皮葡萄球菌(凝固酶阴性葡萄球菌)、棒状杆菌属、单核细胞增多性李斯德杆菌、奴卡菌属。厌氧菌:产和不产β-内酰胺酶的下列细菌:拟杆菌属(二路拟杆菌、二向拟杆菌、多毛拟杆菌、产黑色素拟杆菌、口腔拟杆菌)、脆弱拟杆菌属(脆弱拟杆菌、普通拟杆菌、卵园拟杆菌、多形拟杆菌、单形拟杆菌、不解糖拟杆菌)、消化链球菌属、梭状芽胞杆菌属(难辨梭菌、产气荚膜杆菌)、韦荣氏球菌属、放线菌属。
【适应症】本品适用于对哌拉西林耐药,但对哌拉西林/他唑巴坦敏感的产β-内酰胺酶的细菌引起的中、重度下述感染:
1.由耐哌拉西林、产β-内酰胺酶的大肠杆菌和拟杆菌属(脆弱拟杆菌、卵形拟杆菌、多形拟杆菌或普通拟杆菌)所致的阑尾炎(伴发穿孔或脓肿)和腹膜炎。
2.由耐哌拉西林、产β-内酰胺酶的金黄色葡萄球菌所致的非复杂性和复杂性皮肤及软组织感染,包括蜂窝织炎、皮肤脓肿、缺血性或糖尿病性足部感染。
3.由耐哌拉西林、产β-内酰胺酶的大肠杆菌所致的产后子宫内膜炎或盆腔炎性疾病。
4.由耐哌拉西林、产β-内酰胺酶的流感嗜血杆菌所致的社区获得性肺炎(仅限中度)。
5.由耐哌拉西林、产β-内酰胺酶的金黄色葡萄球菌所致的中、重度医院获得性肺炎(医院内肺炎)。
【用法和用量】将适量本品用20毫升稀释液(0.9%氯化钠注射液或灭菌注射用水),充分溶解后,立即加入250毫升液体(5%葡萄糖注射液或0.9%氯化钠注射液)中,静脉滴注,每次至少30分钟,疗程为7-10天。医院获得性肺炎疗程为7-14天。并可根据病情及细菌学检查结果进行调整。
对于正常肾功能(肌酐清除率≥90毫升/分)患者,成人及12岁以上儿童每次3.375g(含哌拉西林钠3g和他唑巴坦钠0.375g)静脉滴注,每6小时1次。治疗医院内肺炎时,起始量为每次3.375g,每4小时1次,同时合并使用氨基糖苷类药物;如果未分离出绿脓假单胞菌可根据感染程度及病情考虑停用氨基糖苷类药物。
对于肾功能不全患者,推荐的用量见下表:
肌酐清除率(毫升/分) 推荐用量
>40-90 每次3.375g,每6小时1次,每日总量12g/1.5g
20-40 每次2.25g,每6小时1次,每日总量8g/1.0g
<20 每次2.25g,每8小时1次,每日总量6g/0.75g
对于血透患者,每次最大剂量为2.25g,每8小时1次,并在每次血透后可追加0.75g。
【不良反应】
1.本品常见不良反应有:
1) 皮肤反应:如皮疹、瘙痒等;
2) 消化道反应:如腹泻、恶心、呕吐等;
3) 过敏反应;
4) 局部反应:如注射局部刺激反应、疼痛、静脉炎、血栓性静脉炎和水肿等。
5) 其他反应:如血小板减少、胰腺炎、发热、发热伴嗜酸粒细胞增多、腹泻或转氨酶升高等。 这些反应发生在本品和氨基糖苷类药物联合治疗时。
2.此外,本品尚可见下列不良反应:
1)腹泻、便秘、恶心、呕吐、腹痛、消化不良等;
2)斑丘疹、疱疹、荨麻疹、湿疹、瘙痒等;
3)烦躁、头晕、焦虑等;
4)其他反应:如鼻炎、呼吸困难等。
【禁忌】本品禁用于对青霉素类、头孢类抗生素或β-内酰胺酶抑制剂过敏者。
【注意事项】
1.在使用本品前,应详细询问患者对青霉素类药物、头孢菌素类药物、β内酰胺酶抑制剂有无过敏史。治疗中,若发生过敏反应,应立即停药,并给予适当处理,包括吸氧、静脉应用糖皮质激素等。
2.治疗期间,若患者出现腹泻症状,应考虑是否有伪膜性肠炎发生。若诊断确立,应采取相应治疗措施,包括维持水、电解质平衡、补充蛋白等。
3.本品含钠,需要控制盐摄入量的患者使用本品时,应定期检查血清电解质水平;对于同时接受细胞毒药物或利尿剂治疗的患者,要警惕发生低血钾症的可能。
4.当治疗由绿脓假单胞菌引起的医院内肺炎时,应与氨基糖苷类药物联合使用。
5.孕妇、哺乳期妇女慎用。
6.应定期检查造血功能,特别是对疗程≥21天的患者。
7.12岁以下儿童使用本品的安全有效性尚不清楚。
8.现有的临床研究资料表明本品对于医院内下呼吸道感染及复杂性尿路感染的疗效不佳。
9.药物相互作用:
氨基糖苷类:
体外试验中,本品与氨基糖苷类药物同用,可以灭活氨基糖苷类药物。
当本品与妥布霉素同用时,由于哌拉西林/他唑巴坦可能使妥布霉素失活,使妥布霉素的曲线下面积、肾脏清除率及尿中排泄将分别下降11%、32%和38%。严重肾功能不全患者如血透患者,联合应用妥布霉素与哌拉西林时,前者的药代动力学将会发生变化。
丙磺舒:
本品与丙磺舒联合应用,可以使哌拉西林半衰期延长21%,他唑巴坦半衰期延长71%。
万古霉素:
本品与万古霉素联合应用时,药代动力学不受影响。
皮下注射肝素、口服抗凝药物或其它可能影响血液凝固与血小板功能的药物时,应考虑监测凝血功能。
10.本品不能与其他药物在注射器或输液瓶中混合。本品与其它抗生素同用时,必须分开给药。本品不得与只含碳酸氢钠的溶液混合,不得加入血液制品及水解蛋白液。

PIPERACILLIN AND TAZOBACTAM - piperacillin sodium and tazobactam sodium injection, powder, for solution 
APP Pharmaceuticals, LLC
----------
Rx only

To reduce the development of drug-resistant bacteria and maintain the effectiveness of piperacillin and tazobactam for injection and other antibacterial drugs, piperacillin and tazobactam for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.

DESCRIPTION

Piperacillin and tazobactam for injection is an injectable antibacterial combination product consisting of the semisynthetic antibiotic piperacillin sodium and the ß-lactamase inhibitor tazobactam sodium for intravenous administration.

Piperacillin sodium is derived from D(-)-α-aminobenzyl-penicillin.  The chemical name of piperacillin sodium is sodium (2S,5R,6R)-6-[(R)-2-(4-ethyl-2,3-dioxo-1-piperazinecarboxamido)-2-phenylacetamido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate.  The chemical structure of piperacillin sodium is:

Tazobactam sodium, a derivative of the penicillin nucleus, is a penicillanic acid sulfone. Its chemical name is sodium (2S,3S,5R)-3-methyl-7-oxo-3-(1H-1,2,3-triazol-1-ylmethyl)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate-4,4-dioxide.  The chemical structure of tazobactam sodium is:

Piperacillin and tazobactam for injection, piperacillin/tazobactam parenteral combination, is a white to off-white sterile, cryodesiccated powder consisting of piperacillin and tazobactam as their sodium salts packaged in glass vials.  The product does not contain excipients or preservatives.

Each piperacillin and tazobactam for injection 2.25 g single dose vial contains an amount of drug sufficient for withdrawal of piperacillin sodium equivalent to 2 grams of piperacillin and tazobactam sodium equivalent to 0.25 g of tazobactam.

Each piperacillin and tazobactam for injection 3.375 g single dose vial contains an amount of drug sufficient for withdrawal of piperacillin sodium equivalent to 3 grams of piperacillin and tazobactam sodium equivalent to 0.375 g of tazobactam.

Each piperacillin and tazobactam for injection 4.5 g single dose vial contains an amount of drug sufficient for withdrawal of piperacillin sodium equivalent to 4 grams of piperacillin and tazobactam sodium equivalent to 0.5 g of tazobactam.

Piperacillin and tazobactam for injection is a monosodium salt of piperacillin and a monosodium salt of tazobactam containing a total of 2.35 mEq (54 mg) of Na+ per gram of piperacillin in the combination product.

CLINICAL PHARMACOLOGY

Adults

Peak plasma concentrations of piperacillin and tazobactam are attained immediately after completion of an intravenous infusion of piperacillin and tazobactam for injection. Piperacillin plasma concentrations, following a 30-minute infusion of piperacillin and tazobactam for injection, were similar to those attained when equivalent doses of piperacillin were administered alone, with mean peak plasma concentrations of approximately 134, 242, and 298 mcg/mL for the 2.25 g, 3.375 g, and 4.5 g piperacillin and tazobactam doses, respectively.  The corresponding mean peak plasma concentrations of tazobactam were 15, 24 and 34 mcg/mL, respectively.

Following a 30-minute IV infusion of 3.375 g piperacillin and tazobactam for injection every 6 hours, steady-state plasma concentrations of piperacillin and tazobactam were similar to those attained after the first dose.  In like manner, steady-state plasma concentrations were not different from those attained after the first dose when 2.25 g or 4.5 g doses of piperacillin and tazobactam were administered via 30-minute infusions every 6 hours.  Steady-state plasma concentrations after 30-minute infusions every 6 hours are provided in Table 1.

Following single or multiple piperacillin and tazobactam doses to healthy subjects, the plasma half-life of piperacillin and of tazobactam ranged from 0.7 to 1.2 hours and was unaffected by dose or duration of infusion.

Piperacillin is metabolized to a minor microbiologically active desethyl metabolite.  Tazobactam is metabolized to a single metabolite that lacks pharmacological and antibacterial activities.  Both piperacillin and tazobactam are eliminated via the kidney by glomerular filtration and tubular secretion.  Piperacillin is excreted rapidly as unchanged drug with 68% of the administered dose excreted in the urine.  Tazobactam and its metabolite are eliminated primarily by renal excretion with 80% of the administered dose excreted as unchanged drug and the remainder as the single metabolite.  Piperacillin, tazobactam and desethyl piperacillin are also secreted into the bile.

Both piperacillin and tazobactam are approximately 30% bound to plasma proteins.  The protein binding of either piperacillin or tazobactam is unaffected by the presence of the other compound.  Protein binding of the tazobactam metabolite is negligible.

Piperacillin and tazobactam are widely distributed into tissues and body fluids including intestinal mucosa, gallbladder, lung, female reproductive tissues (uterus, ovary, and fallopian tube), interstitial fluid, and bile.  Mean tissue concentrations are generally 50% to 100% of those in plasma.  Distribution of piperacillin and tazobactam into cerebrospinal fluid is low in subjects with non-inflamed meninges, as with other penicillins.

After the administration of single doses of piperacillin/tazobactam to subjects with renal impairment, the half-life of piperacillin and of tazobactam increases with decreasing creatinine clearance.  At creatinine clearance below 20 mL/min, the increase in half-life is twofold for piperacillin and fourfold for tazobactam compared to subjects with normal renal function.  Dosage adjustments for piperacillin and tazobactam for injection are recommended when creatinine clearance is below 40 mL/min in patients receiving the usual recommended daily dose of piperacillin and tazobactam for injection (see DOSAGE AND ADMINISTRATION section for specific recommendations for the treatment of patients with renal insufficiency).

Hemodialysis removes 30% to 40% of a piperacillin/tazobactam dose with an additional 5% of the tazobactam dose removed as the tazobactam metabolite.  Peritoneal dialysis removes approximately 6% and 21% of the piperacillin and tazobactam doses, respectively, with up to 16% of the tazobactam dose removed as the tazobactam metabolite.  For dosage recommendations for patients undergoing hemodialysis, see DOSAGE AND ADMINISTRATION section.

The half-life of piperacillin and of tazobactam increases by approximately 25% and 18%, respectively, in patients with hepatic cirrhosis compared to healthy subjects.  However, this difference does not warrant dosage adjustment of piperacillin and tazobactam for injection due to hepatic cirrhosis.

TABLE 1:  STEADY STATE MEAN PLASMA CONCENTRATIONS IN ADULTS AFTER 30-MINUTE INTRAVENOUS INFUSION OF PIPERACILLIN/TAZOBACTAM EVERY 6 HOURS

PIPERACILLIN


Plasma Concentrations** (mcg/mL)

AUC**

(mcg•hr/mL)

Piperacillin/

Tazobactam

Dosea

No. of

Evaluable

Subjects



30 min



1 hr



2 hr



3 hr



4 hr



6 hr



AUC0-6

2.25 g

8

134

(14)

57

(14)

17.1

(23)

5.2

(32)

2.5

(35)

0.9

(14)b

131 (14)

3.375 g

6

242

(12)

106

(8)

34.6

(20)

11.5

(19)

5.1

(22)

1

(10)

242 (10)

4.5 g

8

298

(14)

141

(19)

46.6

(28)

16.4

(29)

6.9

(29)

1.4

(30)

322 (16)

TAZOBACTAM


Plasma Concentrations** (mcg/mL)

AUC**

(mcg•hr/mL)

Piperacillin/

Tazobactam

Dosea

No. of

Evaluable

Subjects



30 min



1 hr



2 hr



3 hr



4 hr



6 hr



AUC0-6

2.25 g

8

14.8

(14)

7.2

(22)

2.6

(30)

1.1

(35)

0.7

(6)c

<0.5

16 (21)

3.375 g

6

24.2

(14)

10.7

(7)

4.0

(18)

1.4

(21)

0.7

(16)b

<0.5

25 (8)

4.5 g

8

33.8

(15)

17.3

(16)

6.8

(24)

2.8

(25)

1.3

(30)

<0.5

39.8 (15)

** Numbers in parentheses are coefficients of variation (CV%).

a: Piperacillin and tazobactam were given in combination.

b: N = 4

c: N = 3

Pediatrics

Piperacillin and tazobactam pharmacokinetics were studied in pediatric patients 2 months of age and older.  The clearance of both compounds is slower in the younger patients compared to older children and adults. 

In a population PK analysis, estimated clearance for 9 month-old to 12 year-old patients was comparable to adults, with a population mean (SE) value of 5.64 (0.34) mL/min/kg.  The piperacillin clearance estimate is 80% of this value for pediatric patients 2 to 9 months old.  In patients younger than 2 months of age, clearance of piperacillin is slower compared to older children; however, it is not adequately characterized for dosing recommendations.  The population mean (SE) for piperacillin distribution volume is 0.243 (0.011) L/kg and is independent of age.

Microbiology

Piperacillin sodium exerts bactericidal activity by inhibiting septum formation and cell wall synthesis of susceptible bacteria.  In vitro, piperacillin is active against a variety of gram-positive and gram-negative aerobic and anaerobic bacteria.  Tazobactam sodium has little clinically relevant in vitro activity against bacteria due to its reduced affinity to penicillin-binding proteins.  It is, however, a ß-lactamase inhibitor of the Richmond-Sykes class III (Bush class 2b & 2b') penicillinases and cephalosporinases.   It varies in its ability to inhibit class II and IV (2a & 4) penicillinases.  Tazobactam does not induce chromosomally-mediated ß-lactamases at tazobactam concentrations achieved with the recommended dosage regimen.

Piperacillin/tazobactam has been shown to be active against most strains of the following microorganisms both in vitro and in clinical infections as described in the INDICATIONS AND USAGE section.

Aerobic and facultative Gram-positive microorganisms

Staphylococcus aureus (excluding methicillin and oxacillin-resistant isolates)

Aerobic and facultative Gram-negative microorganisms

Acinetobacter baumanii

Escherichia coli

Haemophilus influenzae (excluding ß-lactamase negative, ampicillin-resistant isolates)

Klebsiella pneumoniae

Pseudomonas aeruginosa (given in combination with an aminoglycoside to which the isolate is susceptible)

Gram-negative anaerobes

Bacteroides fragilis group (B. fragilis, B. ovatus, B. thetaiotaomicron, and B. vulgatus)

The following in vitro data are available, but their clinical significance is unknown.

At least 90% of the following microorganisms exhibit an in vitro minimum inhibitory concentration (MIC) less than or equal to the susceptible breakpoint for piperacillin/tazobactam.  However, the safety and effectiveness of piperacillin/tazobactam in treating clinical infections due to these bacteria have not been established in adequate and well-controlled clinical trials.

Aerobic and facultative Gram-positive microorganisms

Enterococcus faecalis (ampicillin or penicillin-susceptible isolates only)

Staphylococcus epidermidis (excluding methicillin and oxacillin-resistant isolates)

Streptococcus agalactiae

Streptococcus pneumoniae (penicillin-susceptible isolates only)

Streptococcus pyogenes

Viridans group streptococci

Aerobic and facultative Gram-negative microorganisms

Citrobacter koseri

Moraxella catarrhalis

Morganella morganii

Neisseria gonorrhoeae

Proteus mirabilis

Proteus vulgaris

Serratia marcescens

Providencia stuartii

Providencia rettgeri

Salmonella enterica

Gram-positive anaerobes

Clostridium perfringens

Gram-negative anaerobes

Bacteroides distasonis

Prevotella melaninogenica

† These are not ß-lactamase producing bacteria and, therefore, are susceptible to piperacillin alone.


Susceptibility Testing Methods

As is recommended with all antimicrobials, the results of in vitro susceptibility tests, when available, should be provided to the physician as periodic reports, which describe the susceptibility profile of nosocomial and community-acquired pathogens.  These reports should aid the physician in selecting the most effective antimicrobial.

Dilution Techniques:  Quantitative methods are used to determine antimicrobial minimum inhibitory concentrations (MICs).  These MICs provide estimates of the susceptibility of bacteria to antimicrobial compounds.  These MICs should be determined using a standardized procedure.  Standardized procedures are based on a dilution method (broth or agar) or equivalent with standardized inoculum concentrations and standardized concentrations of piperacillin and tazobactam powders.1,2  MIC values should be determined using serial dilutions of piperacillin combined with a fixed concentration of 4 mcg/mL tazobactam.  The MIC values obtained should be interpreted according to criteria provided in Table 2.

Diffusion Technique:  Quantitative methods that require measurement of zone diameters also provide reproducible estimates of the susceptibility of  bacteria to antimicrobial compounds.  One such standardized procedure1,3 requires the use of standardized inoculum concentrations.  This procedure uses paper disks impregnated with 100 mcg of piperacillin and 10 mcg of tazobactam to test the susceptibility of microorganisms to piperacillin/tazobactam.  The disk diffusion interpreted criteria are provided in Table 2.

Anaerobic Techniques

For anaerobic bacteria, the susceptibility to piperacillin/tazobactam can be determined by the reference agar dilution method.4

TABLE 2:  SUSCEPTIBILITY INTERPRETIVE CRITERIA FOR PIPERACILLIN/TAZOBACTAM


Susceptibility Test Result Interpretive Criteria


Minimal Inhibitory Concentration

(MIC in mcg/mL)

Disk Diffusion

(Zone Diameter in mm)

Pathogen

S

I

R

S

I

R

Enterobacteriaceae and Acinetobacter baumanii

≤ 16

32 - 64

≥ 128

≥ 21

18 - 20

 

≤ 17


Haemophilus influenzaea

≤ 1

-

≥ 2

-

-

-

Pseudomonas aeruginosa

≤ 64

-

≥ 128

≥ 18

-

≤ 17

Staphylococcus aureus

≤ 8

-

≥ 16

≥ 20

-

≤ 19

Bacteroides fragilis group

≤ 32

64

≥ 128

-

-

-

a: These interpretive criteria for Haemophilus influenzae are applicable only to tests performed using Haemophilus Test Medium inoculated with a direct colony suspension and incubated at 35°C in ambient air for 20 to 24 hours.

A report of S (“Susceptible”) indicates that the pathogen is likely to be inhibited if the antimicrobial compound in the blood reaches the concentration usually achievable.  A report of I (“Intermediate”) indicates that the results should be considered equivocal, and if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated.  This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where high dosage of drug can be used.  This category also provides a buffer zone, which prevents small, uncontrolled technical factors from causing major discrepancies in interpretation.  A report of R (“Resistant”) indicates that the pathogen is not likely to be inhibited if the antimicrobial compound in the blood reaches the concentration usually achievable; other therapy should be considered.

Quality Control

Standardized susceptibility test procedures require the use of quality control microorganisms to control the technical aspects of the test procedures.1,2,3,4  Standard piperacillin/tazobactam powder should provide the following ranges of values noted in Table 3.  Quality control microorganisms are specific strains of microorganisms with intrinsic biological properties relating to resistance mechanisms and their genetic expression within the microorganism; the specific strains used for microbiological quality control are not clinically significant.

TABLE 3:  ACCEPTABLE QUALITY CONTROL RANGES FOR PIPERACILLIN/TAZOBACTAM TO BE USED IN VALIDATION OF SUSCEPTIBILITY TEST RESULTS


Acceptable Quality Control Ranges

QC Strain

Minimal Inhibitory Concentration

Range (MIC in mcg/mL)

Disk Diffusion

Zone Diameter Ranges in mm

Escherichia coli

ATCC 25922

1-4

24-30

Escherichia coli

ATCC 35218

0.5-2

24-30

Pseudomonas aeruginosa

ATCC 27853

1-8

25-33

Haemophilus influenzaea

ATCC 49247

0.06-0.5

-

Staphylococcus aureus

ATCC 29213

0.25-2

-

Staphylococcus aureus

ATCC 25923

-

27-36

Bacteroides fragilis

ATCC 25285

0.12-0.5

-

Bacteroides thetaiotamicron

ATCC 29741

4-16

-

a:  This quality control range for Haemophilus influenzae is applicable only to tests performed using Haemophilus Test Medium inoculated with a direct colony suspension and incubated at 35°C in ambient air for 20 to 24 hours.

INDICATIONS AND USAGE

Piperacillin and tazobactam for injection is indicated for the treatment of patients with moderate to severe infections caused by piperacillin-resistant, piperacillin/tazobactam-susceptible, ß-lactamase producing strains of the designated microorganisms in the specified conditions listed below:

Appendicitis (complicated by rupture or abscess) and peritonitis caused by piperacillin-resistant, ß-lactamase producing strains of Escherichia coli or the following members of the Bacteroides fragilis group:  B. fragilis, B. ovatus, B. thetaiotaomicron, or B. vulgatus.  The individual members of this group were studied in less than 10 cases.

Uncomplicated and complicated skin and skin structure infections, including cellulitis, cutaneous abscesses and ischemic/diabetic foot infections caused by piperacillin-resistant, ß-lactamase producing strains of Staphylococcus aureus.

Postpartum endometritis or pelvic inflammatory disease caused by piperacillin-resistant, ß-lactamase producing strains of Escherichia coli.

Community-acquired pneumonia (moderate severity only) caused by piperacillin-resistant, ß-lactamase producing strains of Haemophilus influenzae.

Nosocomial pneumonia (moderate to severe) caused by piperacillin-resistant, ß-lactamase producing strains of Staphylococcus aureus and by piperacillin/tazobactam-susceptible Acinetobacter baumanii, Haemophilus influenzae, Klebsiella pneumoniae, and Pseudomonas aeruginosa (Nosocomial pneumonia caused by P. aeruginosa should be treated in combination with an aminoglycoside) (see DOSAGE AND ADMINISTRATION).

Piperacillin and tazobactam for injection is indicated only for the specified conditions listed above.  Infections caused by piperacillin-susceptible organisms, for which piperacillin has been shown to be effective, are also amenable to piperacillin and tazobactam for injection treatment due to its piperacillin content.  The tazobactam component of this combination product does not decrease the activity of the piperacillin component against piperacillin-susceptible organisms.  Therefore, the treatment of mixed infections caused by piperacillin-susceptible organisms and piperacillin-resistant, ß-lactamase producing organisms susceptible to piperacillin and tazobactam for injection should not require the addition of another antibiotic (see DOSAGE AND ADMINISTRATION).

Piperacillin and tazobactam for injection is useful as presumptive therapy in the indicated conditions prior to the identification of causative organisms because of its broad spectrum of bactericidal activity against gram-positive and gram-negative aerobic and anaerobic organisms.

Appropriate cultures should usually be performed before initiating antimicrobial treatment in order to isolate and identify the organisms causing infection and to determine their susceptibility to piperacillin and tazobactam for injection.  Antimicrobial therapy should be adjusted, if appropriate, once the results of culture(s) and antimicrobial susceptibility testing are known.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of piperacillin and tazobactam for injection and other antibacterial drugs, piperacillin and tazobactam for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.  When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy.  In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

CONTRAINDICATIONS

Piperacillin and tazobactam for injection is contraindicated in patients with a history of allergic reactions to any of the penicillins, cephalosporins, or ß-lactamase inhibitors.

WARNINGS

SERIOUS AND OCCASIONALLY FATAL HYPERSENSITIVITY (ANAPHYLACTIC/ANAPHYLACTOID) REACTIONS (INCLUDING SHOCK) HAVE BEEN REPORTED IN PATIENTS RECEIVING THERAPY WITH PENICILLINS INCLUDING PIPERACILLIN AND TAZOBACTAM FOR INJECTION. THESE REACTIONS ARE MORE LIKELY TO OCCUR IN INDIVIDUALS WITH A HISTORY OF PENICILLIN HYPERSENSITIVITY OR A HISTORY OF SENSITIVITY TO MULTIPLE ALLERGENS.  THERE HAVE BEEN REPORTS OF INDIVIDUALS WITH A HISTORY OF PENICILLIN HYPERSENSITIVITY WHO HAVE EXPERIENCED SEVERE REACTIONS WHEN TREATED WITH CEPHALOSPORINS.  BEFORE INITIATING THERAPY WITH PIPERACILLIN AND TAZOBACTAM FOR INJECTION, CAREFUL INQUIRY SHOULD BE MADE CONCERNING PREVIOUS HYPERSENSITIVITY REACTIONS TO PENICILLINS, CEPHALOSPORINS, OR OTHER ALLERGENS.  IF AN ALLERGIC REACTION OCCURS, PIPERACILLIN AND TAZOBACTAM FOR INJECTION SHOULD BE DISCONTINUED AND APPROPRIATE THERAPY INSTITUTED.  SERIOUS ANAPHYLACTIC/ ANAPHYLACTOID REACTIONS (INCLUDING SHOCK) REQUIRE IMMEDIATE EMERGENCY TREATMENT WITH EPINEPHRINE.  OXYGEN, INTRAVENOUS STEROIDS, AND AIRWAY MANAGEMENT, INCLUDING INTUBATION, SHOULD ALSO BE ADMINISTERED AS INDICATED.

Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including piperacillin and tazobactam for injection, and may range in severity from mild diarrhea to fatal colitis.  Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile.

C. difficile produces toxins A and B which contribute to the development of CDAD.  Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea following antibiotic use.  Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.

If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.

PRECAUTIONS

General

Bleeding manifestations have occurred in some patients receiving ß-lactam antibiotics, including piperacillin.  These reactions have sometimes been associated with abnormalities of coagulation tests such as clotting time, platelet aggregation and prothrombin time, and are more likely to occur in patients with renal failure.  If bleeding manifestations occur, piperacillin and tazobactam for injection should be discontinued and appropriate therapy instituted.

The possibility of the emergence of resistant organisms that might cause superinfections should be kept in mind.  If this occurs, appropriate measures should be taken.

As with other penicillins, patients may experience neuromuscular excitability or convulsions if higher than recommended doses are given intravenously (particularly in the presence of renal failure).

Piperacillin and tazobactam for injection is a monosodium salt of piperacillin and a monosodium salt of tazobactam and contains a total of 2.35 mEq (54 mg) of Na+ per gram of piperacillin in the combination product.  This should be considered when treating patients requiring restricted salt intake.  Periodic electrolyte determinations should be performed in patients with low potassium reserves, and the possibility of hypokalemia should be kept in mind with patients who have potentially low potassium reserves and who are receiving cytotoxic therapy or diuretics.

As with other semisynthetic penicillins, piperacillin therapy has been associated with an increased incidence of fever and rash in cystic fibrosis patients.

In patients with creatinine clearance ≤ 40 mL/min and dialysis patients (hemodialysis and CAPD), the intravenous dose should be adjusted to the degree of renal function impairment (see DOSAGE AND ADMINISTRATION).

Prescribing piperacillin and tazobactam for injection in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of development of drug-resistant bacteria.

Information for Patients

Patients should be counseled that antibacterial drugs including piperacillin and tazobactam for injection should only be used to treat bacterial infections.  They do not treat viral infections (e.g., the common cold).  When piperacillin and tazobactam for injection is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed.  Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by piperacillin and tazobactam for injection or other antibacterial drugs in the future.

Diarrhea is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued.  Sometimes after starting treatment with antibiotics, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as two or more months after having taken the last dose of the antibiotic.  If this occurs, patients should contact their physician as soon as possible.

Laboratory Tests

Periodic assessment of hematopoietic function should be performed, especially with prolonged therapy, ie, ≥ 21 days (see ADVERSE REACTIONS, Adverse Laboratory Events).

Drug Interactions

Aminoglycosides

The mixing of beta-lactam antibiotics with aminoglycosides in vitro can result in substantial inactivation of the aminoglycoside.  However, amikacin and gentamicin have been shown to be compatible in vitro with piperacillin and tazobactam in certain diluents at specific concentrations for a simultaneous Y-site infusion (see DOSAGE AND ADMINISTRATION).

The inactivation of aminoglycosides in the presence of penicillin-class drugs has been recognized.  It has been postulated that penicillin-aminoglycoside complexes form; these complexes are microbiologically inactive and of unknown toxicity.  Sequential administration of piperacillin and tazobactam with tobramycin to patients with normal renal function and mild to moderate renal impairment has been shown to modestly decrease serum concentrations of tobramycin but does not significantly affect tobramycin pharmacokinetics.  When aminoglycosides are administered in combination with piperacillin to patients with end-stage renal disease requiring hemodialysis, the concentrations of the aminoglycosides (especially tobramycin) may be significantly altered and should be monitored.  Since aminoglycosides are not equally susceptible to inactivation by piperacillin, consideration should be given to the choice of the aminoglycoside when administered in combination with piperacillin to these patients.

Probenecid

Probenecid administered concomitantly with piperacillin and tazobactam prolongs the half-life of piperacillin by 21% and that of tazobactam by 71%.

Vancomycin

No pharmacokinetic interactions have been noted between piperacillin/tazobactam and vancomycin.

Heparin

Coagulation parameters should be tested more frequently and monitored regularly during simultaneous administration of high doses of heparin, oral anticoagulants, or other drugs that may affect the blood coagulation system or the thrombocyte function.

Vecuronium

Piperacillin when used concomitantly with vecuronium has been implicated in the prolongation of the neuromuscular blockade of vecuronium.  Piperacillin and tazobactam could produce the same phenomenon if given along with vecuronium.  Due to their similar mechanism of action, it is expected that the neuromuscular blockade produced by any of the non-depolarizing muscle relaxants could be prolonged in the presence of piperacillin.  (See package insert for vecuronium bromide.)

Methotrexate

Limited data suggests that co-administration of methotrexate and piperacillin may reduce the clearance of methotrexate due to competition for renal secretion.  The impact of tazobactam on the elimination of methotrexate has not been evaluated.  If concurrent therapy is necessary, serum concentrations of methotrexate as well as the signs and symptoms of methotrexate toxicity should be frequently monitored.

Drug/Laboratory Test Interactions

As with other penicillins, the administration of piperacillin and tazobactam for injection may result in a false-positive reaction for glucose in the urine using a copper-reduction method (CLINITEST®).  It is recommended that glucose tests based on enzymatic glucose oxidase reactions (such as DIASTIX® or TES-TAPE®) be used.

There have been reports of positive test results using the Bio-Rad Laboratories Platelia Aspergillus EIA test in patients receiving piperacillin/tazobactam injection who were subsequently found to be free of Aspergillus infection.  Cross-reactions with non-Aspergillus polysaccharides and polyfuranoses with the Bio-Rad Laboratories Platelia Aspergillus EIA test have been reported.

Therefore, positive test results in patients receiving piperacillin/tazobactam should be interpreted cautiously and confirmed by other diagnostic methods.

Carcinogenesis, Mutagenesis, Impairment of Fertility

Long-term carcinogenicity studies in animals have not been conducted with piperacillin/tazobactam, piperacillin, or tazobactam.

Piperacillin/Tazobactam

Piperacillin/tazobactam was negative in microbial mutagenicity assays at concentrations up to 14.84/1.86 mcg/plate.  Piperacillin/tazobactam was negative in the unscheduled DNA synthesis (UDS) test at concentrations up to 5689/711 mcg/mL.  Piperacillin/tazobactam was negative in a mammalian point mutation (Chinese hamster ovary cell HPRT) assay at concentrations up to 8000/1000 mcg/mL.  Piperacillin/tazobactam was negative in a mammalian cell (BALB/c-3T3) transformation assay at concentrations up to 8/1 mcg/mL.  In vivo, piperacillin/tazobactam did not induce chromosomal aberrations in rats dosed IV with 1500/187.5 mg/kg; this dose is similar to the maximum recommended human daily dose on a body-surface-area basis (mg/m2).

Piperacillin

Piperacillin was negative in microbial mutagenicity assays at concentrations up to 50 mcg/plate.  There was no DNA damage in bacteria (Rec assay) exposed to piperacillin at concentrations up to 200 mcg/disk.  Piperacillin was negative in the UDS test at concentrations up to 10,000 mcg/mL.  In a mammalian point mutation (mouse lymphoma cells) assay, piperacillin was positive at concentrations ≥2500 mcg/mL.  Piperacillin was negative in a cell (BALB/c-3T3) transformation assay at concentrations up to 3000 mcg/mL.  In vivo, piperacillin did not induce chromosomal aberrations in mice at IV doses up to 2000 mg/kg/day or rats at IV doses up to 1500 mg/kg/day.  These doses are half (mice) or similar (rats) to the maximum recommended human daily dose based on body-surface area (mg/m2).  In another in vivo test, there was no dominant lethal effect when piperacillin was administered to rats at IV doses up to 2000 mg/kg/day, which is similar to the maximum recommended human daily dose based on body-surface area (mg/m2).  When mice were administered piperacillin at IV doses up to 2000 mg/kg/day, which is half the maximum recommended human daily dose based on body-surface area (mg/m2), urine from these animals was not mutagenic when tested in a microbial mutagenicity assay.  Bacteria injected into the peritoneal cavity of mice administered piperacillin at IV doses up to 2000 mg/kg/day did not show increased mutation frequencies.

Tazobactam

Tazobactam was negative in microbial mutagenicity assays at concentrations up to 333 mcg/plate.  Tazobactam was negative in the UDS test at concentrations up to 2000 mcg/mL.  Tazobactam was negative in a mammalian point mutation (Chinese hamster ovary cell HPRT) assay at concentrations up to 5000 mcg/mL.  In another mammalian point mutation (mouse lymphoma cells) assay, tazobactam was positive at concentrations ≥3000 mcg/mL.  Tazobactam was negative in a cell (BALB/c-3T3) transformation assay at concentrations up to 900 mcg/mL.  In an in vitro cytogenetics (Chinese hamster lung cells) assay, tazobactam was negative at concentrations up to 3000 mcg/mL.  In vivo, tazobactam did not induce chromosomal aberrations in rats at IV doses up to 5000 mg/kg, which is 23 times the maximum recommended human daily dose based on body-surface area (mg/m2).

Pregnancy: Teratogenic Effects-Pregnancy Category B

Piperacillin/tazobactam

Reproduction studies have been performed in rats and have revealed no evidence of impaired fertility due to piperacillin/tazobactam administered up to a dose which is similar to the maximum recommended human daily dose based on body-surface area (mg/m2).

Teratology studies have been performed in mice and rats and have revealed no evidence of harm to the fetus due to piperacillin/tazobactam administered up to a dose which is 1 to 2 times and 2 to 3 times the human dose of piperacillin and tazobactam, respectively, based on body-surface area (mg/m2).

Piperacillin and tazobactam cross the placenta in humans.

Piperacillin

Reproduction and teratology studies have been performed in mice and rats and have revealed no evidence of impaired fertility or harm to the fetus due to piperacillin administered up to a dose which is half (mice) or similar (rats) to the maximum recommended human daily dose based on body-surface area (mg/m2).

Tazobactam

Reproduction studies have been performed in rats and have revealed no evidence of impaired fertility due to tazobactam administered at doses up to 3 times the maximum recommended human daily dose based on body-surface area (mg/m2).

Teratology studies have been performed in mice and rats and have revealed no evidence of harm to the fetus due to tazobactam administered at doses up to 6 and 14 times, respectively, the human dose based on body-surface area (mg/m2).  In rats, tazobactam crosses the placenta.  Concentrations in the fetus are less than or equal to 10% of those found in maternal plasma.

There are, however, no adequate and well-controlled studies with the piperacillin/tazobactam combination or with piperacillin or tazobactam alone in pregnant women.  Because animal reproduction studies are not always predictive of the human response, this drug should be used during pregnancy only if clearly needed.

Nursing Mothers

Piperacillin is excreted in low concentrations in human milk; tazobactam concentrations in human milk have not been studied.  Caution should be exercised when piperacillin and tazobactam for injection is administered to a nursing woman.

Pediatric Use

Use of piperacillin and tazobactam for injection in pediatric patients 2 months of age or older with appendicitis and/or peritonitis is supported by evidence from well-controlled studies and pharmacokinetic studies in adults and in pediatric patients.  This includes a prospective, randomized, comparative, open-label clinical trial with 542 pediatric patients 2 to 12 years of age with complicated intra-abdominal infections, in which 273 pediatric patients received piperacillin/tazobactam.  Safety and efficacy in pediatric patients less than 2 months of age have not been established (see CLINICAL PHARMACOLOGY and DOSAGE AND ADMINISTRATION).

There are no dosage recommendations for piperacillin and tazobactam for injection in pediatric patients with impaired renal function.

Geriatric Use

Patients over 65 years are not at an increased risk of developing adverse effects solely because of age.  However, dosage should be adjusted in the presence of renal insufficiency (see DOSAGE AND ADMINISTRATION).

In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

Piperacillin and tazobactam for injection contains 54 mg (2.35 mEq) of sodium per gram of piperacillin in the combination product.  At the usual recommended doses, patients would receive between 648 and 864 mg/day (28.2 and 37.6 mEq) of sodium.  The geriatric population may respond with a blunted natriuresis to salt loading.  This may be clinically important with regard to such diseases as congestive heart failure.

This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function.  Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

ADVERSE REACTIONS

Adverse Events From Clinical Trials

During the initial clinical investigations, 2621 patients worldwide were treated with piperacillin and tazobactam for injection in phase 3 trials.  In the key North American clinical trials (n=830 patients), 90% of the adverse events reported were mild to moderate in severity and transient in nature.  However, in 3.2% of the patients treated worldwide, piperacillin and tazobactam for injection was discontinued because of adverse events primarily involving the skin (1.3%), including rash and pruritus; the gastrointestinal system (0.9%), including diarrhea, nausea, and vomiting; and allergic reactions (0.5%).

Adverse local reactions that were reported, irrespective of relationship to therapy with piperacillin and tazobactam for injection, were phlebitis (1.3%), injection site reaction (0.5%), pain (0.2%), inflammation (0.2%), thrombophlebitis (0.2%), and edema (0.1%).

Based on patients from the North American trials (n=1063), the events with the highest incidence in patients, irrespective of relationship to piperacillin and tazobactam for injection therapy, were diarrhea (11.3%); headache (7.7%); constipation (7.7%); nausea (6.9%); insomnia (6.6%); rash (4.2%), including maculopapular, bullous, urticarial, and eczematoid; vomiting (3.3%); dyspepsia (3.3%); pruritus (3.1%); stool changes (2.4%); fever (2.4%); agitation (2.1%); pain (1.7%); moniliasis (1.6%); hypertension (1.6%); dizziness (1.4%); abdominal pain (1.3%); chest pain (1.3%); edema (1.2%); anxiety (1.2%); rhinitis (1.2%); and dyspnea (1.1%).

Additional adverse systemic clinical events reported in 1% or less of the patients in the initial North American trials are listed below within each body system.

Autonomic nervous system—hypotension, ileus, syncope

Body as a whole—rigors, back pain, malaise

Cardiovascular—tachycardia, including supraventricular and ventricular; bradycardia; arrhythmia, including atrial fibrillation, ventricular fibrillation, cardiac arrest, cardiac failure, circulatory failure, myocardial infarction

Central nervous system—tremor, convulsions, vertigo

Gastrointestinal—melena, flatulence, hemorrhage, gastritis, hiccough, ulcerative stomatitis

Pseudomembranous colitis was reported in one patient during the clinical trials.  The onset of pseudomembranous colitis symptoms may occur during or after antibacterial treatment (see WARNINGS).

Hearing and Vestibular System—tinnitus

Hypersensitivity—anaphylaxis

Metabolic and Nutritional—symptomatic hypoglycemia, thirst

Musculoskeletal—myalgia, arthralgia

Platelets, Bleeding, Clotting—mesenteric embolism, purpura, epistaxis, pulmonary embolism (see PRECAUTIONS, General).

Psychiatric—confusion, hallucination, depression

Reproductive, Female—leukorrhea, vaginitis

Respiratory—pharyngitis, pulmonary edema, bronchospasm, coughing

Skin and Appendages—genital pruritus, diaphoresis

Special senses—taste perversion

Urinary—retention, dysuria, oliguria, hematuria, incontinence

Vision—photophobia

Vascular (extracardiac)—flushing

Nosocomial Pneumonia Trials 

In a completed study of nosocomial lower respiratory tract infections, 222 patients were treated with piperacillin and tazobactam for injection in a dosing regimen of 4.5 g every 6 hours in combination with an aminoglycoside and 215 patients were treated with imipenem/cilastatin (500 mg/500 mg q6h) in combination with an aminoglycoside.  In this trial, treatment-emergent adverse events were reported by 402 patients, 204 (91.9%) in the piperacillin/tazobactam group and 198 (92.1%) in the imipenem/cilastatin group.  Twenty-five (11%) patients in the piperacillin/tazobactam group and 14 (6.5%) in the imipenem/cilastatin group (p > 0.05) discontinued treatment due to an adverse event.

In this study of piperacillin and tazobactam for injection in combination with an aminoglycoside, adverse events that occurred in more than 1% patients and were considered by the investigator to be drug-related were: diarrhea (17.6%), fever (2.7%), vomiting (2.7%), urinary tract infection (2.7%), rash (2.3%), abdominal pain (1.8%), generalized edema (1.8%), moniliasis (1.8%), nausea (1.8%), oral moniliasis (1.8%), BUN increased (1.8%), creatinine increased (1.8%), peripheral edema (1.8%), abdomen enlarged (1.4%), headache (1.4%), constipation (1.4%), liver function tests abnormal (1.4%), thrombocythemia (1.4%), excoriations (1.4%), and sweating (1.4%).

Drug-related adverse events reported in 1% or less of patients in the nosocomial pneumonia study of piperacillin and tazobactam for injection with an aminoglycoside were: acidosis, acute kidney failure, agitation, alkaline phosphatase increased, anemia, asthenia, atrial fibrillation, chest pain, CNS depression, colitis, confusion, convulsion, cough increased, thrombocytopenia, dehydration, depression, diplopia, drug level decreased, dry mouth, dyspepsia, dysphagia, dyspnea, dysuria, eosinophilia, fungal dermatitis, gastritis, glossitis, grand mal convulsion, hematuria, hyperglycemia, hypernatremia, hypertension, hypertonia, hyperventilation, hypochromic anemia, hypoglycemia, hypokalemia, hyponatremia, hypophosphatemia, hypoxia, ileus, injection site edema, injection site pain, injection site reaction, kidney function abnormal, leukocytosis, leukopenia, local reaction to procedure, melena, pain, prothrombin decreased, pruritus, respiratory disorder, SGOT increased, SGPT increased, sinus bradycardia, somnolence, stomatitis, stupor, tremor, tachycardia, ventricular extrasystoles, and ventricular tachycardia.

In a previous nosocomial pneumonia study conducted with a dosing regimen of 3.375 g given every 4 hours with an aminoglycoside, the following adverse events, irrespective of drug relationship, were observed: diarrhea (20%); constipation (8.4%); agitation (7.1%); nausea (5.8%); headache (4.5%); insomnia (4.5%); oral thrush (3.9%); erythematous rash (3.9%); anxiety (3.2%); fever (3.2%); pain (3.2%); pruritus (3.2%); hiccough (2.6%); vomiting (2.6%); dyspepsia (1.9%); edema (1.9%); fluid overload (1.9%); stool changes (1.9%); anorexia (1.3%); cardiac arrest (1.3%); confusion (1.3%); diaphoresis (1.3%); duodenal ulcer (1.3%); flatulence (1.3%); hypertension (1.3%); hypotension (1.3%); inflammation at injection site (1.3%); pleural effusion (1.3%); pneumothorax (1.3%); rash, not otherwise specified (1.3%); supraventricular tachycardia (1.3%); thrombophlebitis (1.3%); and urinary incontinence (1.3%).

Adverse events irrespective of drug relationship observed in 1% or less of patients in the above study with piperacillin and tazobactam for injection and an aminoglycoside included: aggressive reaction (combative), angina, asthenia, atelectasis, balanoposthitis, cerebrovascular accident, chest pain, conjunctivitis, deafness, dyspnea, earache, ecchymosis, fecal incontinence, gastric ulcer, gout, hemoptysis, hypoxia, pancreatitis, perineal irritation/pain, urinary tract infection with trichomonas, vitamin B12 deficiency anemia, xerosis, and yeast in urine.

Pediatrics

Studies of piperacillin and tazobactam for injection in pediatric patients suggest a similar safety profile to that seen in adults.  In a prospective, randomized, comparative, open-label clinical trial of pediatric patients with severe intra-abdominal infections (including appendicitis and/or peritonitis), 273 patients were treated with piperacillin and tazobactam for injection (112.5 mg/kg every 8 hours) and 269 patients were treated with cefotaxime (50 mg/kg) plus metronidazole (7.5 mg/kg) every 8 hours.  In this trial, treatment-emergent adverse events were reported by 146 patients, 73 (26.7%) in the piperacillin and tazobactam for injection group and 73 (27.1%) in the cefotaxime/metronidazole group.  Six patients (2.2%) in the piperacillin and tazobactam for injection group and 5 patients (1.9%) in the cefotaxime/metronidazole group discontinued due to an adverse event.

In this study, adverse events that were reported in more than 1% of patients, irrespective of relationship to therapy with piperacillin and tazobactam for injection were: diarrhea (7%), fever (4.8%), vomiting (3.7%), local reaction (3.3%), abscess (2.2%), sepsis (2.2%), abdominal pain (1.8%), infection (1.8%), bloody diarrhea (1.1%), pharyngitis (1.5%), constipation (1.1%) and SGOT increase (1.1%).

Adverse events reported in 1% or less of pediatric patients receiving piperacillin and tazobactam for injection are consistent with adverse events reported in adults.

Additional controlled studies in pediatric patients showed a similar safety profile as that described above.

Post-Marketing Experience

Additional adverse events reported from worldwide marketing experience with piperacillin and tazobactam for injection, occurring under circumstances where causal relationship to piperacillin and tazobactam for injection is uncertain:

Gastrointestinal—hepatitis, cholestatic jaundice

Hematologic—hemolytic anemia, anemia, thrombocytosis, agranulocytosis, pancytopenia

Immune—hypersensitivity reactions, anaphylactic/anaphylactoid reactions (including shock)

Infections—candidal superinfections

Renal—interstitial nephritis, renal failure

Skin and Appendages—erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis

Post-marketing experience with piperacillin and tazobactam for injection in pediatric patients suggests a similar safety profile to that seen in adults.

Adverse Laboratory Events (Seen During Clinical Trials)

Of the studies reported, including that of nosocomial lower respiratory tract infections in which a higher dose of piperacillin and tazobactam for injection was used in combination with an aminoglycoside, changes in laboratory parameters, without regard to drug relationship, include:

Hematologic—decreases in hemoglobin and hematocrit, thrombocytopenia, increases in platelet count, eosinophilia, leukopenia, neutropenia.  The leukopenia/neutropenia associated with piperacillin and tazobactam for injection administration appears to be reversible and most frequently associated with prolonged administration, ie, ≥21 days of therapy.  These patients were withdrawn from therapy; some had accompanying systemic symptoms (e.g., fever, rigors, chills).

Coagulation—positive direct Coombs’ test, prolonged prothrombin time, prolonged partial thromboplastin time

Hepatic—transient elevations of AST (SGOT), ALT (SGPT), alkaline phosphatase, bilirubin

Renal—increases in serum creatinine, blood urea nitrogen

Urinalysis—proteinuria, hematuria, pyuria

Additional laboratory events include abnormalities in electrolytes (ie, increases and decreases in sodium, potassium, and calcium), hyperglycemia, decreases in total protein or albumin, blood glucose decreased, gamma-glutamyltransferase increased, hypokalemia, and bleeding time prolonged.

The following adverse reaction has also been reported for piperacillin for injection:

Skeletal—prolonged muscle relaxation (see PRECAUTIONS, Drug Interactions).

Piperacillin therapy has been associated with an increased incidence of fever and rash in cystic fibrosis patients.

To report SUSPECTED ADVERSE EVENTS, contact FDA at 1-800-FDA-1088 or www.fda.gov.

OVERDOSAGE

There have been postmarketing reports of overdose with piperacillin/tazobactam.  The majority of those events experienced, including nausea, vomiting, and diarrhea, have also been reported with the usual recommended dosages.  Patients may experience neuromuscular excitability or convulsions if higher than recommended doses are given intravenously (particularly in the presence of renal failure).

Treatment should be supportive and symptomatic according the patient’s clinical presentation. Excessive serum concentrations of either piperacillin or tazobactam may be reduced by hemodialysis.  Following a single 3.375 g dose of piperacillin/tazobactam, the percentage of the piperacillin and tazobactam dose removed by hemodialysis was approximately 31% and 39%, respectively (see CLINICAL PHARMACOLOGY).

DOSAGE AND ADMINISTRATION

Piperacillin and tazobactam for injection should be administered by intravenous infusion over 30 minutes.

The usual total daily dose of piperacillin and tazobactam for injection for adults is 3.375 g every six hours totaling 13.5 g (12 g piperacillin/1.5 g tazobactam).

Nosocomial Pneumonia

Initial presumptive treatment of patients with nosocomial pneumonia should start with piperacillin and tazobactam for injection at a dosage of 4.5 g every six hours plus an aminoglycoside, totaling 18 g (16 g piperacillin/2 g tazobactam).  Treatment with the aminoglycoside should be continued in patients from whom Pseudomonas aeruginosa is isolated.  If Pseudomonas aeruginosa is not isolated, the aminoglycoside may be discontinued at the discretion of the treating physician.

Due to the in vitro inactivation of the aminoglycoside by beta-lactam antibiotics, piperacillin and tazobactam and the aminoglycoside are recommended for separate administration.  Piperacillin and tazobactam and the aminoglycoside should be reconstituted, diluted, and administered separately when concomitant therapy with aminoglycosides is indicated (see PRECAUTIONS, Drug Interactions).

In circumstances where co-administration via Y-site is necessary, piperacillin and tazobactam is compatible for simultaneous co-administration via Y-site infusion only with the following aminoglycosides under the following conditions:

                                                         TABLE 4

Aminoglycoside

Piperacillin

and Tazobactam Dose (grams)

Piperacillin and Tazobactam Diluent Volume (mL)

Aminoglycoside Concentration Range* (mg/mL)

Acceptable Diluents

Amikacin

2.25, 3.375, 4.5

50, 100, 150

1.75 to 7.5

0.9%Sodium Chloride or 5% Dextrose

Gentamicin

2.25, 3.375, 4.5

100, 150

0.7 to 3.32

0.9% Sodium Chloride

*The concentration ranges in Table 4 are based on administration of the aminoglycoside in divided doses (10 to 15 mg/kg/day in two daily doses for amikacin and 3 to 5 mg/kg/day in three daily doses for gentamicin).  Administration of amikacin or gentamicin in a single daily dose or in doses exceeding those stated above via Y-site with piperacillin and tazobactam has not been evaluated.  See package insert for each aminoglycoside for complete dosage and administration instructions.

Piperacillin and tazobactam is not compatible with tobramycin for simultaneous co-administration via Y-site infusion.  Compatibility of piperacillin and tazobactam with other aminoglycosides has not been established.  Only the concentration and diluents for amikacin or gentamicin with the dosages of piperacillin and tazobactam listed above have been established as compatible for co-administration via Y-site infusion.  Simultaneous co-administration via Y-site infusion in any manner other than listed above may result in inactivation of the aminoglycoside by piperacillin and tazobactam.

Renal Insufficiency

In patients with renal insufficiency (Creatinine Clearance ≤ 40 mL/min), the intravenous dose of piperacillin and tazobactam for injection should be adjusted to the degree of actual renal function impairment.  In patients with nosocomial pneumonia receiving concomitant aminoglycoside therapy, the aminoglycoside dosage should be adjusted according to the recommendations of the manufacturer.  The recommended daily doses of piperacillin and tazobactam for injection for patients with renal insufficiency are as follows:

Recommended Dosing of Piperacillin and Tazobactam for injection in Patients with Normal Renal Function and Renal Insufficiency (As total grams piperacillin/tazobactam)

Renal Function

(Creatinine Clearance,

mL/min)

All Indications

(except nosocomial pneumonia)

Nosocomial Pneumonia

>40 mL/min

3.375 q 6 h

4.5 q 6 h

20 to 40 mL/min*

2.25 q 6 h

3.375 q 6 h

<20 mL/min*

2.25 q 8 h

2.25 q 6 h

Hemodialysis**

2.25 q 12 h

2.25 q 8 h

CAPD

2.25 q 12 h

2.25 q 8 h

* Creatinine clearance for patients not receiving hemodialysis

** 0.75 g should be administered following each hemodialysis session on hemodialysis days

For patients on hemodialysis, the maximum dose is 2.25 g every twelve hours for all indications other than nosocomial pneumonia and 2.25 g every eight hours for nosocomial pneumonia.  Since hemodialysis removes 30% to 40% of the administered dose, an additional dose of 0.75 g piperacillin and tazobactam for injection should be administered following each dialysis period on hemodialysis days.  No additional dosage of piperacillin and tazobactam for injection is necessary for CAPD patients.

Duration of Therapy

The usual duration of piperacillin and tazobactam for injection treatment is from seven to ten days.  However, the recommended duration of piperacillin and tazobactam for injection treatment of nosocomial pneumonia is 7 to 14 days.  In all conditions, the duration of therapy should be guided by the severity of the infection and the patient's clinical and bacteriological progress.

Pediatric Patients

For children with appendicitis and/or peritonitis 9 months of age or older, weighing up to 40 kg, and with normal renal function, the recommended piperacillin and tazobactam for injection dosage is 100 mg piperacillin/12.5 mg tazobactam per kilogram of body weight, every 8 hours. For pediatric patients between 2 months and 9 months of age, the recommended piperacillin and tazobactam for injection dosage based on pharmacokinetic modeling, is 80 mg piperacillin/10 mg tazobactam per kilogram of body weight, every 8 hours (see PRECAUTIONS, General, Pediatric Use and CLINICAL PHARMACOLOGY).  Pediatric patients weighing over 40 kg and with normal renal function should receive the adult dose.  There are no dosage recommendations for piperacillin and tazobactam for injection in pediatric patients with impaired renal function.

Directions for Reconstitution and Dilution for Use

Intravenous Administration

For conventional vials, reconstitute piperacillin and tazobactam for injection per gram of piperacillin with 5 mL of a compatible reconstitution diluent from the list provided below.

2.25 g, 3.375 g, and 4.5 g piperacillin and tazobactam for injection should be reconstituted with 10 mL, 15 mL, and 20 mL, respectively.  Swirl until dissolved.

Pharmacy vials should be used immediately after reconstitution.  Discard any unused portion after 24 hours if stored at room temperature 20° to 25°C (68° to 77°F), or after 48 hours if stored at refrigerated temperature 2° to 8°C (36° to 46°F).

Compatible Reconstitution Diluents

0.9% Sodium Chloride for Injection

Sterile Water for Injection

Dextrose 5%

Bacteriostatic Saline/Parabens

Bacteriostatic Water/Parabens

Bacteriostatic Saline/Benzyl Alcohol

Bacteriostatic Water/Benzyl Alcohol

Reconstituted piperacillin and tazobactam for injection solution should be further diluted (recommended volume per dose of 50 mL to 150 mL) in a compatible intravenous diluent solution listed below.  Administer by infusion over a period of at least 30 minutes.  During the infusion it is desirable to discontinue the primary infusion solution.

Compatible Intravenous Diluent Solutions

0.9% Sodium Chloride for Injection

Sterile Water for Injection

Dextrose 5%

Dextran 6% in Saline
LACTATED RINGER’S SOLUTION IS NOT COMPATIBLE WITH PIPERACILLIN AND TAZOBACTAM FOR INJECTION.

Maximum recommended volume per dose of Sterile Water for Injection is 50 mL.

Piperacillin and tazobactam for injection should not be mixed with other drugs in a syringe or infusion bottle since compatibility has not been established.

Piperacillin and tazobactam for injection is not chemically stable in solutions that contain only sodium bicarbonate and solutions that significantly alter the pH.

Piperacillin and tazobactam for injection should not be added to blood products or albumin hydrolysates.

Piperacillin and tazobactam for injection can be used in ambulatory intravenous infusion pumps.

Stability of Piperacillin and Tazobactam for Injection Following Reconstitution

Piperacillin and tazobactam for injection is stable in glass and plastic containers (plastic syringes, IV bags and tubing) when used with compatible diluents.

Pharmacy vials should be used immediately after reconstitution.  Discard any unused portion after 24 hours if stored at room temperature 20° to 25°C (68° to 77°F), or after 48 hours if stored at refrigerated temperature 2° to 8°C (36° to 46°F).  Vials should not be frozen after reconstitution.

Stability studies in the IV bags have demonstrated chemical stability (potency, pH of reconstituted solution and clarity of solution) for up to 24 hours at room temperature and up to one week at refrigerated temperature.  Piperacillin and tazobactam for injection contains no preservatives.  Appropriate consideration of aseptic technique should be used.

Stability of piperacillin and tazobactam for injection in an ambulatory intravenous infusion pump has been demonstrated for a period of 12 hours at room temperature.  Each dose was reconstituted and diluted to a volume of 37.5 mL or 25 mL.  One-day supplies of dosing solution were aseptically transferred into the medication reservoir (IV bags or cartridge).  The reservoir was fitted to a preprogrammed ambulatory intravenous infusion pump per the manufacturer’s instructions.  Stability of piperacillin and tazobactam for injection is not affected when administered using an ambulatory intravenous infusion pump.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

HOW SUPPLIED

Piperacillin and Tazobactam for Injection is supplied in the following sizes:

Each Piperacillin and Tazobactam for Injection 2.25 g single-dose vial provides piperacillin sodium equivalent to 2 grams of piperacillin and tazobactam sodium equivalent to 0.25 g tazobactam.  Each vial contains 4.7 mEq (108 mg) of sodium.  Supplied 10 per box - Product Code 300920, NDC 63323-309-20.

Each Piperacillin and Tazobactam for Injection 3.375 g single-dose vial provides piperacillin sodium equivalent to 3 grams of piperacillin and tazobactam sodium equivalent to 0.375 g tazobactam.  Each vial contains 7.0 mEq (162 mg) of sodium.  Supplied 10 per box - Product Code 301020, NDC 63323-300-20.

Each Piperacillin and Tazobactam for Injection 4.5 g single-dose vial provides piperacillin sodium equivalent to 4 grams of piperacillin and tazobactam sodium equivalent to 0.5 g tazobactam.  Each vial contains 9.4 mEq (216 mg) of sodium.  Supplied 10 per box - Product Code 302050, NDC 63323-320-50.

Store Piperacillin and Tazobactam for Injection dry powder at 20°C to 25°C (68°F to 77°F) [see USP Controlled Room Temperature] prior to reconstitution.



责任编辑:admin


相关文章
特治星注射剂(piperacillin/tazobactam,TAZOCIN)
PIPERACILLIN/TAZOBACTAM(哌拉西林/他唑巴坦)注射液
特治星注射液|Tazocin(piperacillin/ tazobactam)
特治星(注射用哌拉西林钠/他唑巴坦钠)
 

最新文章

更多

· Penicillin G Sodium In...
· 青霉素V钾片|PENICILLIN...
· 氨苄西林钠注射剂|VICCI...
· PENTCILLIN(哌拉西林溶解...
· 哌拉西林注射液|PENTCIL...
· Begalin-P PD(舒巴坦钠...
· 注射用哌拉西林钠Taiper...
· Dalacin Capsules(盐酸...
· 氟氯西林钠注射剂和胶囊...
· 磺苄西林钠注射粉剂(KED...

推荐文章

更多

· Penicillin G Sodium In...
· 青霉素V钾片|PENICILLIN...
· 氨苄西林钠注射剂|VICCI...
· PENTCILLIN(哌拉西林溶解...
· 哌拉西林注射液|PENTCIL...
· Begalin-P PD(舒巴坦钠...
· 注射用哌拉西林钠Taiper...
· Dalacin Capsules(盐酸...
· 氟氯西林钠注射剂和胶囊...
· 磺苄西林钠注射粉剂(KED...

热点文章

更多